Showing 16,981 - 17,000 results of 44,775 for search '(( 50 ((ns decrease) OR (a decrease)) ) OR ( 5 ((ng decrease) OR (mean decrease)) ))', query time: 1.06s Refine Results
  1. 16981
  2. 16982
  3. 16983
  4. 16984
  5. 16985

    A. We randomly selected 20 mutually exclusive groups of protein complexes that contained exactly five subunits; we mapped the corresponding gene pairs to SINaTRA scores, and plotte... by Alexandra Jacunski (5665486)

    Published 2015
    “…We compared the fraction of gene pairs with products in the same vs. different complexes for three SINaTRA cutoffs (0.95, 0.80, 0.50) as well as for all gene pairs. A SINaTRA cutoff of 0.95 has approximately half of its pairs associated with the same complex; however, a decrease in the cutoff shifts this balance. …”
  6. 16986

    Data_Sheet_1_Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.docx by Tatsuhiko Wada (14391781)

    Published 2023
    “…</p>Results<p>Overall, 112 and 109 patients were randomized to ivermectin and placebo, respectively; 106 patients from each group were included in the full analysis set (male [%], mean age: 68.9%, 47.9 years [ivermectin]; 62.3%, 47.5 years [placebo]). …”
  7. 16987

    Data_Sheet_1_Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.docx by Tatsuhiko Wada (14391781)

    Published 2023
    “…</p>Results<p>Overall, 112 and 109 patients were randomized to ivermectin and placebo, respectively; 106 patients from each group were included in the full analysis set (male [%], mean age: 68.9%, 47.9 years [ivermectin]; 62.3%, 47.5 years [placebo]). …”
  8. 16988

    Data_Sheet_1_Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.docx by Tatsuhiko Wada (14391781)

    Published 2023
    “…</p>Results<p>Overall, 112 and 109 patients were randomized to ivermectin and placebo, respectively; 106 patients from each group were included in the full analysis set (male [%], mean age: 68.9%, 47.9 years [ivermectin]; 62.3%, 47.5 years [placebo]). …”
  9. 16989
  10. 16990
  11. 16991

    Fluorescence time-lapse imaging of a single GPR3-HT-expressing CGN. by Tatsuhiro Miyagi (847543)

    Published 2016
    “…<p>(A-B) The CGNs were transfected with the pGPR3-HT expression vector and were plated onto 0.03% PEI-coated plates. …”
  12. 16992

    (A) Effect of calcium chelators and K channel antagonist, ChTX on fEPSP during OGD. by Shirin Jalini (2551054)

    Published 2016
    “…<b>(</b>B) Effect of calcium chelators, and BK channel antagonist on recovery of fEPSP after OGD. BAPTA-AM (1 μM) decreases recovery time from 2 min (n = 7), 4 min (n = 6) and 6 min (n = 3) of <i>in vitro</i> OGD compared to control (n = 7, 5, 5, respectively). …”
  13. 16993
  14. 16994
  15. 16995
  16. 16996

    Nick closing activity of <i>w</i>Bm-LigA and biochemical characterization. by Nidhi Shrivastava (315987)

    Published 2013
    “…<p>(A) Effect of enzyme substrate ratio on nick closing activity. …”
  17. 16997
  18. 16998
  19. 16999
  20. 17000